Try our corporate solution for free!

Leading pharmaceutical M&A deal value in China 2019, by acquirer

Value of leading investment deals of mergers and acquisitions(M&A) in the pharmaceutical sector in China as of 2019, by acquirer

Exclusive Premium statistic

You need a Statista Account for unlimited access.

  • Full access to 1m statistics
  • Incl. source references
  • Available to download in PNG, PDF, XLS format
Statista Accounts

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2020

Region

China

Survey time period

2019

Supplementary notes

*Other acquirers involved in the investment deal included OrbiMed Capital, Yongjin Capital, Hillhouse Capital, Cormorant, Vivo, Shanghai Pharma (HK).

The deal value figures refer only to the deals whereby a value has been publicly disclosed.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical industry in the United Kingdom (UK)"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.